The short version of metabolic research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-25 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Hydrothermal vents in the deep ocean typically form along the mid-ocean ridges, such as the East Pacific Rise and the Mid-Atlantic Ridge. These are locations where two tectonic plates are diverging and new crust is being formed. The water that issues from seafloor hydrothermal vents consists mostly of seawater drawn into the hydrothermal system close to the volcanic edifice through faults and porous sediments or volcanic strata, plus some magmatic water released by the upwelling magma. On land, the majority of water circulated within fumarole and geyser systems is meteoric water and ground water that has percolated down into the hydrothermal system from the surface, but also commonly contains some portion of metamorphic water, magmatic water, and sedimentary formational brine released by the magma. The proportion of each varies from location to location. In contrast to the approximately 2 °C (36 °F) ambient water temperature at these depths, water emerges from these vents at temperatures ranging from 60 °C (140 °F) up to as high as 464 °C (867 °F). Due to the high hydrostatic pressure at these depths, water may exist in either its liquid form or as a supercritical fluid at such temperatures. The critical point of (pure) water is 375 °C (707 °F) at a pressure of 218 atmospheres.
In 1947, Raleigh citizens adopted a council–manager form of government, which is still the city's current form of government. The Dorton Arena, a 7,610-seat multi-purpose arena designed by Matthew Nowicki, was opened in 1952 on the grounds of the North Carolina State Fair. It was listed in the National Register of Historic Places in 1973.
=== Catalysts and reagents === Because Fe is inexpensive and nontoxic, much effort has been devoted to the development of Fe-based catalysts and reagents. Iron is however less common as a catalyst in commercial processes than more expensive metals. In biology, Fe-containing enzymes are pervasive. Iron catalysts are traditionally used in the Haber–Bosch process for the production of ammonia and the Fischer–Tropsch process for conversion of carbon monoxide to hydrocarbons for fuels and lubricants. Powdered iron in an acidic medium is used in the Bechamp reduction, the conversion of nitrobenzene to aniline.
Sources: en.wikipedia.org
rare-earth element Also called rare-earth metals or used interchangeably with lanthanides. Any of the 17 nearly indistinguishable, silvery-white, soft, heavy metallic elements belonging to a set including the lanthanide series (atomic numbers 57 through 71) as well as scandium and yttrium.
Thus the product formation rate depends on the enzyme concentration as well as on the substrate concentration, the equation resembles a bimolecular reaction with a corresponding pseudo-second order rate constant
The first one to systematically expand and correct the chemical potentials of Bohr's atomic theory was Walther Kossel in 1914 and in 1916. Kossel explained that in the periodic table new elements would be created as electrons were added to the outer shell. In Kossel's paper, he writes: This leads to the conclusion that the electrons, which are added further, should be put into concentric rings or shells, on each of which ... only a certain number of electrons—namely, eight in our case—should be arranged. As soon as one ring or shell is completed, a new one has to be started for the next element; the number of electrons, which are most easily accessible, and lie at the outermost periphery, increases again from element to element and, therefore, in the formation of each new shell the chemical periodicity is repeated. In a 1919 paper, Irving Langmuir postulated the existence of "cells" which we now call orbitals, which could each only contain eight electrons each, and these were arranged in "equidistant layers" which we now call shells. He made an exception for the first shell to only contain two electrons. The chemist Charles Rugeley Bury suggested in 1921 that eight and eighteen electrons in a shell form stable configurations. Bury proposed that the electron configurations in transitional elements depended upon the valence electrons in their outer shell. He introduced the word transition to describe the elements now known as transition metals or transition elements.
Sources: en.wikipedia.org
Tier 1: Tier 1 assembly is the standard Golden Gate assembly, and genes are assembled from their components parts (DNA parts coding for genetic elements like UTRs, promoters, ribosome binding sites or terminator sequences). Flanking the insertion site of the tier 1 destination vectors are a pair of inward cutting BpiI restriction sites. This allows these plasmids to be used as entry vectors for tier two destination vectors. Tier 2: Tier 2 assembly involves further assembling the genes assembled in tier 1 assembly into multi-gene constructs. If there is a need for further, higher tier assembly, inward cutting BsaI restriction sites can be added to flank the insertion sites. These vectors can then be used as entry vectors for higher tier constructs. Each assembly tier alternates the use of BsaI and BpiI restriction sites to minimise the number of forbidden sites, and sequential assembly for each tier is achieved by following the Golden Gate plasmid design. Overall, the MoClo standard allows for the assembly of a construct that contains multiple transcription units, all assembled from different DNA parts, by a series of one-pot Golden Gate reactions. However, one drawback of the MoClo standard is that it requires the use of 'dummy parts' with no biological function, if the final construct requires less than four component parts. The Golden Braid standard on the other hand introduced a pairwise Golden Gate assembly standard. The Golden Braid standard uses the same tiered assembly as MoClo, but each tier only involves the assembly of two DNA fragments, i.e. a pairwise approach.
An osteochondrodysplasia, or skeletal dysplasia, is a disorder of the development of bone and cartilage. Osteochondrodysplasias are rare diseases. About 1 in 5,000 babies are born with some type of skeletal dysplasia. Nonetheless, if taken collectively, genetic skeletal dysplasias or osteochondrodysplasias comprise a recognizable group of genetically determined disorders with generalized skeletal affection. These disorders lead to disproportionate short stature and bone abnormalities, particularly in the arms, legs, and spine. Skeletal dysplasia can result in marked functional limitation and even mortality. Osteochondrodysplasias or skeletal dysplasia subtypes can overlap in clinical aspects, therefore plain radiography is absolutely necessary to establish an accurate diagnosis. Magnetic resonance imaging can provide further diagnostic insights and guide treatment strategies especially in cases of spinal involvement. As some disorders that cause skeletal dysplasia have treatments available, early diagnosis is particularly important, but may be challenging due to overlapping features and symptoms that may also be common in unaffected children.
==== Documentary films ==== Detox or Die (2004). Directed by David Graham Scott. Scott begins videotaping his heroin-addicted friends. Before long, he himself is addicted to the drug. He eventually turns the camera on himself and his family. After 12 years of debilitating, painful dependence on methadone, Scott turns to ibogaine. Filmed in Scotland and England, and broadcast on BBC One as the third installment in the documentary series One Life. Ibogaine: Rite of Passage (2004). Directed by Ben Deloenen. Cy, a 34-year-old heroin addict, undergoes ibogaine treatment with Dr. Martin Polanco at the Ibogaine Association, a clinic in Rosarito, Mexico. Deloenen interviews people formerly addicted to heroin, cocaine, and methamphetamine, who share their perspectives about ibogaine treatment. In Gabon, a Babongo woman receives iboga root for her depressive malaise. Deloenen visually contrasts this Western, clinical use of ibogaine with the Bwiti use of iboga root, but emphasizes the Western context. Facing the Habit (2007). Directed by Magnolia Martin. Martin's subject is a former millionaire and stockbroker who travels to Mexico for ibogaine treatment for heroin addiction. Tripping in Amsterdam (2008). In this short film directed by Jan Bednarz, Simon "Swany" Wan visits Sara Glatt's iboga treatment center in Amsterdam. Current TV broadcast the documentary in 2008 as part of their "Quarter-life Crisis" programming roster. I'm Dangerous with Love (2009). Directed by Michel Negroponte.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.